Nurullah İlhan,MD· @drnurullahilhan · X·· 17 小时前评分70
正文 · 原文
#NATALEE at 6 years: sustained iDFS benefit with adjuvant ribociclib.
iDFS: 83.2% vs 77.9%.
OS favored ribociclib; nominal significance only, with descriptive analysis outside formal testing.
Assoc. Prof. Nurullah İlhan
#ESMO2026 #BreastCancer #OncoTwitter
25 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Nurullah İlhan,MD · x.com